crwepicks'  Instablog

Crown Equity Holdings Inc. (OTC BB: CRWE.OB)

Crown Equity Holdings Inc. announces that its sales this year have already surpassed $1,000,000. This compares to $232,510 for the three quarters ending September 30, 2009 and $ 659,907 total sales for the year 2009.

"Based on our sales to date, we had more than 4 times the sales for the same period last year and are 34% ahead of last year's total sales," commented Kenneth Bosket, President and CEO of Crown Equity Holdings Inc. "Our growth in sales along with our investments in infrastructure and people give the company a basis for supporting future growth of the magnitude we have seen so far this year," stated Bosket.

Crown Equity Holdings Inc. has expanded its internet footprint internationally to include the following 19 countries: Argentina, Australia, Brazil, Canada, China, France, Germany, Hong Kong, India, Ireland, Italy, Japan, Korea, Mexico, New Zealand, Singapore, Spain, Taiwan and the UK.


Crown Equity Holdings, Inc. has increased its workforce to an amount of 35, compared to this time last year’s head count of 6, which is a 580% personnel increase. This is in addition to the 10 contractors we recently hired in Pakistan.

(Source: CLICK HERE)

__________________

Philip Morris International, Inc. (NYSE: PM)

Philip Morris International, Inc. wallstreetequityresearch.com gives shareholders valuable insight on cigarette stocks Philip Morris International Inc. and Lorillard Inc. (NYSE:LO)The cigarette industry is facing a number of challenges recently, as governments around the world continue to increase tobacco taxes, and a new proposed ban on menthol cigarettes in the U.S. could hurt sales for companies such as Lorillard Inc.

Philip Morris International Inc., through its subsidiaries, engages in the manufacture and sale of cigarettes and other tobacco products in markets outside of the United States. Its international product brand line comprises Marlboro, Merit, Parliament, Virginia Slims, L&M, Chesterfield, Bond Street, Lark, Muratti, Next, Philip Morris, and Red & White. The company also offers its products under the A Mild, Dji Sam Soe, and A Hijau in Indonesia; Diana in Italy; Optima and Apollo-Soyuz in the Russian Federation; Morven Gold in Pakistan; Boston in Colombia; Belmont, Canadian Classics, and Number 7 in Canada; Best and Classic in Serbia; f6 in Germany; Delicados in Mexico; Assos in Greece; and Petra in the Czech Republic and Slovakia

__________________
Charles Schwab Corp. (NYSE: SCHW)

Charles Schwab Corp. Independent registered investment advisors (RIAs) who actively manage their technology investments generate more income and spend considerably less on technology, according to a new report from Charles Schwab Advisor Services. Using results from the 2010 RIA Benchmarking Study and additional interviews with advisors, Integrating Technology into Your Practice: Keys to Improving Productivity divides advisors into two types: those that have a strategic approach to technology and those that take a more passive approach. The study shows that the strategic advisors spend half as much on technology and are twice as profitable compared to the biggest technology spenders (top 20%) of the more passive firms. In addition, the report finds that firms who embed technology into their business and operations see greater productivity and profitability gains, as well as lower client acquisition costs.

__________________


Mylan, Inc. (NasdaqGS: MYL)

Mylan, Inc. announced on October 1, 2010 that its subsidiary Mylan Pharmaceuticals Inc. has launched Bupropion Hydrochloride Extended-release Tablets USP, (XL), 150 mg and 300 mg (Once-Daily), the generic version of GlaxoSmithKline's antidepressant Wellbutrin XL®. Bupropion Hydrochloride Extended-release Tablets had U.S. sales of approximately $752 million for the 12 months ending June 30, 2010, according to IMS Health.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies.







*******************************************
Sign-Up For Free Stock Alerts At crwepicks.com/signup
*******************************************











THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.


*******************************************